We are monitoring the impact of COVID-19 & Recession alarm on LATAM Liver Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Latin America Liver Cancer Therapeutics Market Research Report - Segmented By Type, Therapeutics, End User & Country (Mexico, Brazil, Argentina, Chile & Rest of Latin America) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2022 to 2027)

Published: January, 2022
ID: 782
Pages: 145

Latin America Liver Cancer Therapeutics Market Size (2022 to 2027)

The size of the liver cancer therapeutics market in Latin America was worth USD 97.08 million in 2022 and estimated to be growing at a CAGR of 9.68%, to reach USD 154.08 million by 2027.

The Latin American liver cancer therapeutics market is being propelled forward by a growing aging population, unmet needs for liver cancer treatment, cancer medication inventions, expanding government initiatives, rising cancer occurrences, and rising healthcare spending. In addition, the fifth most common cancer and the third leading cause of cancer-related deaths on the continent is liver cancer. As a result, the market for liver cancer diagnosis and treatment is expected to become more competitive in the next years. Therefore, the Latin American Liver Cancer Therapeutics Market expects to see many novels targeting therapeutics soon.

According to Globocan, 1.2 million new instances of liver cancer have been reported worldwide. Because of expanded research and development activities targeted at treating dangerous diseases, the FDA has approved more medicines for hepatocellular carcinoma, which accounts for 90% of liver cancer. In addition, the usage of alcoholic beverages, smoking, and greater urbanization have all been associated with liver cancer due to increased government support and funding from international health organizations. When a range of treatment choices are available, there may be a surge in demand for liver cancer treatments in the near future. These factors are expected to showcase a positive impact on the Latin American market during the forecast period.

The expansion of the Latin American liver cancer therapies market is hampered by strict regulatory processes, large capital inputs, a low success rate in drug clinical trials, and low accessibility in distant locations. The COVID-19 has had a negative impact on the market for liver cancer therapies. Pharmaceutical businesses are implementing preparations to maintain the supply chain's balance while increasing product sales in response to the COVID 19 emergency. During the COVID 19 crisis, healthcare organizations have set rigorous criteria for handling hepatocellular carcinoma patients. Patients with HCC, according to research, are at significant risk of developing the illness. As a result, patients are classified as emergencies during the crisis.

This research report on the Latin American liver cancer therapeutics market has been segmented and sub-segmented into the following categories

By Type:      

  • Primary    
  • Secondary             
  • Benign Liver growths         

By Therapeutics:

  • Hepatocellular Carcinoma
  • Cholangio carcinoma        
  • Hepatoblastoma  
  • Targeted Therapy

By End Users:

  • Pediatrics
  • Adults    

By Country:

  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Rest of Latin America

The Latin American liver cancer therapeutics market is expected to rise steadily during the forecast period. Changes in people's present lifestyles have exposed a substantial portion of the population to the risk factors that contribute to liver cancer. Hepatocellular carcinoma is the most prevalent type of liver cancer, and it primarily affects people with chronic liver disease such as cirrhosis. Hepatocellular carcinoma is one of the biggest causes of cancer-related death worldwide. The disparity in major risk factors, such as hepatitis C virus (HCV) and hepatitis B virus (HBV) infections, causing the hepatocellular carcinoma in those regions has been observed, resulting in higher incidence rates of hepatocellular carcinoma in the developing Latin American countries than developed countries.

Brazil is expected to be the market leader in the Latin American liver cancer therapeutics market during the projected period. In addition, hepatocellular carcinoma therapies are predicted to be in high demand due to an increase in the frequency of the disease.

After Brazil, Argentina is predicted to hold the second-largest proportion of the Latin American market for liver cancer therapy. The market would be driven by the rising cancer incidence and significant unmet medical requirements in this area over the forecast period.

KEY MARKET PLAYERS:

Companies playing a prominent role in the Latin America liver cancer therapeutics market profiled in this report are Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc., Jennerex Biotherapeutics Inc., Celsion Corp., Bayer Schering Pharma AG, 4SC AG, and Bristol-Myers Squibb Company.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods   

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By Type                     

                             5.1.1 Primary    

                             5.1.2 Secondary             

                             5.1.3 Benign Liver growths         

              5.2 By Therapeutics                     

                             5.2.1 Hepatocellular Carcinoma

                             5.2.2 Cholangio carcinoma        

                             5.2.3 Hepatoblastoma  

                             5.2.4 Targeted Therapy

              5.3 By End-Users                          

                             5.3.1 Pediatrics

                             5.3.2 Adults      

6. Geographical Analysis                                         

                             6.1 Introduction             

                             6.2 Brazil           

                             6.3 Mexico        

                             6.4 Argentina   

                             6.5 Rest of Latin America            

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 Alnylam Pharmaceuticals Inc.                          

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 ImClone Systems Inc.                          

              9.3 Onyx Pharmaceuticals Inc.                 

              9.4 F. Hoffmann-La Roche Ltd.                

              9.5 Pfizer Inc.                  

              9.6 ArQule Inc.               

              9.7 Jennerex Biotherapeutics Inc.                         

              9.8 Celsion Corp.                          

              9.9 Bayer Schering Pharma AG                

              9.10 4SC AG                    

              9.11 Bristol-Myers Squibb Company                    

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  1. Latin America Liver Cancer Diagnostics and Therapeutics Market By Region, From 2022 - 2027 (USD Million)
  2. Latin America Liver Cancer Diagnostics and Therapeutics Market By Type, From 2022 - 2027 (USD Million)
  3. Latin America Primary Market By Region, From 2022 - 2027 (USD Million)
  4. Latin America Secondary Market By Region, From 2022 - 2027 (USD Million)
  5. Latin America Benign Liver growths Market By Region, From 2022 - 2027 (USD Million)
  6. Latin America Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2022 - 2027 (USD Million)
  7. Latin America Hepatocellular Carcinoma Market By Region, From 2022 - 2027 (USD Million)
  8. Latin America Cholangio carcinoma Market By Region, From 2022 - 2027 (USD Million)
  9. Latin America Hepatoblastoma Market By Region, From 2022 - 2027 (USD Million)
  10. Latin America Targeted Therapy Market By Region, From 2022 - 2027 (USD Million)
  11. Latin America Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2022 - 2027 (USD Million)
  12. Latin America Pediatrics Market By Region, From 2022 - 2027 (USD Million)
  13. Latin America Adults Market By Region, From 2022 - 2027 (USD Million)
  14. Brazil Liver Cancer Diagnostics and Therapeutics Market By Type, From 2022 - 2027 (USD Million)
  15. Brazil Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2022 - 2027 (USD Million)
  16. Brazil Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2022 - 2027 (USD Million)
  17. Argentina Liver Cancer Diagnostics and Therapeutics Market By Type, From 2022 - 2027 (USD Million)
  18. Argentina Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2022 - 2027 (USD Million)
  19. Argentina Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2022 - 2027 (USD Million)
  20. Mexico Liver Cancer Diagnostics and Therapeutics Market By Type, From 2022 - 2027 (USD Million)
  21. Mexico Liver Cancer Diagnostics and Therapeutics Market By Therapeutics, From 2022 - 2027 (USD Million)
  22. Mexico Liver Cancer Diagnostics and Therapeutics Market By End-Users, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample